Clinical Trial Update: PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update of PTK787/ZK222584 in combination with bevacizumab for patients with refractory or advanced cancers. The study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PTK787/ZK222584 (vatalanib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Refractory Malignancy, Advanced Malignancies | Phase 1 | Status: COMPLETED